Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | XPO1 | O14980 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.48 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488889 | 0.89 | MAPT (0.61) | KIF11GPR35MAPTP2RX1LMNA | |
| SCHEMBL3620508 | 0.84 | GPR35 (0.58) | GPR35MAPTXPO1ALDH1A1P2RX1 | |
| SCHEMBL2910974 | 0.82 | ALDH1A1 (0.61) | KIF11MAPTALDH1A1P2RX1LMNA | |
| SCHEMBL30977688 | 0.82 | MAPT (0.54) | KIF11GPR35MAPTXPO1P2RX1 | |
| SCHEMBL20560661 | 0.82 | XPO1 (0.52) | GPR35MAPTXPO1P2RX1TMPRSS4 | |
| SCHEMBL12144643 | 0.82 | MAPT (0.54) | KIF11GPR35MAPTXPO1P2RX1 | |
| SCHEMBL18724739 | 0.82 | GPR35 (0.43) | GPR35MAPTXPO1P2RX1TMPRSS4 | |
| SCHEMBL16379971 | 0.81 | MAPT (0.57) | KIF11GPR35MAPTALDH1A1P2RX1 | |
| SCHEMBL31356653 | 0.81 | MAPT (0.57) | KIF11GPR35MAPTALDH1A1P2RX1 | |
| SCHEMBL5448110 | 0.81 | ACP1 (0.60) | KIF11GPR35MAPTP2RX1TMPRSS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957485-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Healthcare, LLC (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007064931-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | claimed |
| CN-119630645-A | Flavivirus inhibitors | IRBM股份公司 | 2025-03-14 | — | — | CN | disclosed |
| US-RE47493-E1 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-09 | — | — | US | disclosed |
| US-RE47493-E1 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-09 | — | — | US | disclosed |
| EP-3013798-B1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEIGENE LTD (KY) | 2018-06-27 | — | — | EP | disclosed |
| EP-2964617-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2017-04-12 | — | — | EP | disclosed |
| CN-105732634-A | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | 拜尔健康护理有限责任公司 | 2016-07-06 | — | — | CN | disclosed |
| EP-2964617-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-9115093-B2 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-9115093-B2 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-20090093477-A1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE IN THERAPY | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| CN-101365454-A | Substituted 4-amino-pyrrolotriazine derivatives for the treatment of hyperproliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2009-02-11 | — | — | CN | disclosed |
| CN-101326157-A | Diphenyl urea derivatives | ARPIDA AG (CH) | 2008-12-17 | — | — | CN | disclosed |
| WO-2008135537-A1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-11-13 | — | — | WO | disclosed |
| EP-1957485-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Healthcare, LLC (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008003412-A1 | THE USE OF 1,4-DIARYL-DIHYDROPYRIMIDINE-2-ON DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2008-01-10 | — | — | WO | disclosed |
| CN-1993361-A | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORP (US) | 2007-07-04 | — | — | CN | disclosed |
| WO-2007064931-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | KIF11 1709/4885GPR35 87/4885MAPT 680/4885 |
| US-20090093477-A1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE IN THERAPY | NOX1, NOX3, ELANE | KIF11 4285/4885GPR35 2992/4885MAPT 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.